It's hard to believe that I've now reached the 6-month point of my treatment for Chronic Myeloid Leukemia (CML) at Roswell ...

Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.

Background: Acute myeloid leukemia (AML) is a hematologic tumor with poor prognosis and significant clinical heterogeneity. By integrating transcriptomic data, single-cell RNA sequencing data and ...